Dose response of intravenous sildenafil on systemic and regional hemodynamics in hypoxic neonatal piglets

Shock

Volumn 26, Issue 1, 2006, Pages 99-106

  Haase, Erika ^a   Bigam, David L ^a   Cravetchi, Olga ^a   Cheung, Po Yin ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ROYAL ALEXANDRA HOSPITAL   (Canada)

Author keywords

Blood flow; Newborn; Phosphodiesterase inhibitor; Pulmonary hypertension

Indexed keywords

OXYGEN; SILDENAFIL; SODIUM CHLORIDE; PIPERAZINE DERIVATIVE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ARTERIAL OXYGEN TENSION; ARTERIAL PRESSURE; ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; DOSE RESPONSE; HEART INDEX; HYPOTHESIS; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG HEMODYNAMICS; NEWBORN HYPOXIA; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN SATURATION; OXYGENATION; SUPERIOR MESENTERIC ARTERY; SWINE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; BLOOD FLOW VELOCITY; BLOOD PRESSURE; DRUG EFFECT; HEMODYNAMICS; HYPOXEMIA; KIDNEY; NEWBORN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; VASCULARIZATION;

ANIMALS; ANIMALS, NEWBORN; ANOXEMIA; BLOOD FLOW VELOCITY; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMIC PROCESSES; HYPERTENSION, PULMONARY; KIDNEY; OXYGEN CONSUMPTION; PIPERAZINES; SWINE; VASODILATOR AGENTS;

EID: 33747171462     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000215321.44983.98     Document Type: Article

References (30)

1. Kinsella JP, Abman SH: Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. J Pediatr 126:853-864, 1995.
2. Gersony WM: Neonatal pulmonary hypertension: pathophysiology, classification, and etiology. Clin Perinatol 11:517-524, 1984.
3. Clark RH, Kueser TJ, Walker MW, et al: Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med 342:469-474, 2000.
4. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 336:597-604, 1997.
5. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR: Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107:3230-3235, 2003.
6. Wallis RM, Corbin JD, Francis SH, Ellis P: Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 83:3C-12C, 1999.
7. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47-52, 1996.
8. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR: Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104:424-428, 2001.
9. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105:2398-2403, 2002.
10. Ghofrani HA, Wiedemann R, Rose F, et al: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360:895-900, 2002.
11. Abrams D, Schulze-Neick I, Magee AG: Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84:E4, 2000.
12. Atz AM, Wessel DL: Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 91:307-310, 1999.
13. Schulze-Neick I, Hartenstein P, Li J, et al: Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 108(suppl 1):II167-II173, 2003.
14. Stocker C, Penny DJ, Brizard CP, et al: Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med 29:1996-2003, 2003.
15. Shekerdemian LS, Ravn HB, Penny DJ: Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res 55:413-418, 2004.
16. 2 in newborn pigs. J Perinat Med 24:227-236, 1996.
17. Cheung PY, Barrington KJ, Bigam DL: Temporal effects of prolonged hypoxaemia and reoxygenation on systemic, pulmonary and mesenteric perfusions in newborn piglets. Cardiovasc Res 39:451-458, 1998.
18. Lepore JJ, Maroo A, Pereira NL, et al: Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 90:677-680, 2002.
19. Laupland KB, Helmersen D, Zygun DA, et al: Sildenafil treatment of primary pulmonary hypertension. Can Respir J 10:48-50, 2003.
20. Watanabe H, Ohashi K, Takeuchi K, et al: Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71:398-402, 2002.
21. Mikhail GW, Prasad SK, Li W, et al: Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 25:431-436, 2004.
22. Kleinsasser A, Loeckinger A, Hoermann C, et al: Sildenafil modulates hemodynamics and pulmonary gas exchange. Am J Respir Crit Care Med 163:339-343, 2001.
23. Weimann J, Ullrich R, Hromi J, et al: Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92:1702-1712, 2000.
24. Shekerdemian LS, Ravn HB, Penny DJ: Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 165:1098-1102, 2002.
25. Gillies HC, Roblin D, Jackson G: Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol 86:131-141, 2002.
26. Gratton R, Carmichael L, Homan J, et al: Carotid arterial blood flow in the ovine fetus as a continuous measure of cerebral blood flow. J Soc Gynecol Investig 3:60-65, 1996.
27. Giordano D, De Stefano ME, Citro G, et al: Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta 1539:16-27, 2001.
28. Schulz-Neick I, Redington A: Sildenafil, nitric oxide, and acute lung injury: pathophysiology beats pharmacotherapy? Pediatr Res 55:370-371, 2004.
29. Hill DE: Swine in perinatal research: an overview. In Tumbleson ME (ed.): Swine in Biomedical Research, Vol 1. New York, NY: Plenum Publishing Corporation, pp 1155-1159, 1985.
30. Haworth SG, Hislop AA: Effect of hypoxia on adaptation of the pulmonary circulation to extra-uterine life in the pig. Cardiovasc Res 16:293-303, 1982.